These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39249591)

  • 1. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).
    Simpson E; Fernández-Peñas P; de Bruin-Weller M; Lio PA; Chu CY; Ezzedine K; Agell H; Casillas M; Ding Y; Yang FE; Pierce E; Bieber T
    Adv Ther; 2024 Sep; ():. PubMed ID: 39249591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.
    Lio PA; Armstrong A; Gutermuth J; Nosbaum A; Sofen H; Gil EG; Casillas M; Chen S; Sun L; Pierce E; Elmaraghy H; Dawson Z; Torres T
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1929-1943. PubMed ID: 38922484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.
    Silverberg JI; Wollenberg A; Stein Gold L; Del Rosso J; Yosipovitch G; Lio P; Carrascosa JM; Gallo G; Ding Y; Xu Z; Casillas M; Pierce E; Agell H; Ständer S
    Dermatol Ther (Heidelb); 2024 Aug; 14(8):2249-2260. PubMed ID: 39123054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
    Silverberg JI; Guttman-Yassky E; Thaçi D; Irvine AD; Stein Gold L; Blauvelt A; Simpson EL; Chu CY; Liu Z; Gontijo Lima R; Pillai SG; Seneschal J;
    N Engl J Med; 2023 Mar; 388(12):1080-1091. PubMed ID: 36920778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
    Soung J; Ständer S; Gutermuth J; Pau-Charles I; Dawson Z; Yang FE; Sun L; Pierce E; Elmaraghy H; Stein-Gold L
    J Dermatolog Treat; 2024 Dec; 35(1):2329240. PubMed ID: 38679419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
    Hebert AA; Flohr C; Hong HC; Irvine AD; Pierce E; Elmaraghy H; Pillai S; Dawson Z; Chen S; Armengol C; Siegfried E; Weidinger S
    J Dermatolog Treat; 2024 Dec; 35(1):2324833. PubMed ID: 38735650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks.
    Yosipovitch G; Lio P; Legat FJ; Chovatiya R; Deleuran M; Pierce E; Casillas M; Ding Y; Yang FE; Bardolet L; Ständer S
    Dermatol Ther (Heidelb); 2024 Aug; 14(8):2171-2180. PubMed ID: 39002092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
    Blauvelt A; Thyssen JP; Guttman-Yassky E; Bieber T; Serra-Baldrich E; Simpson E; Rosmarin D; Elmaraghy H; Meskimen E; Natalie CR; Liu Z; Xu C; Pierce E; Morgan-Cox M; Garcia Gil E; Silverberg JI
    Br J Dermatol; 2023 May; 188(6):740-748. PubMed ID: 36994947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Silverberg JI; Wollenberg A; Reich A; Thaçi D; Legat FJ; Papp KA; Stein Gold L; Bouaziz JD; Pink AE; Carrascosa JM; Rewerska B; Szepietowski JC; Krasowska D; Havlíčková B; Kalowska M; Magnolo N; Pauser S; Nami N; Sauder MB; Jain V; Padlewska K; Cheong SY; Fleuranceau Morel P; Ulianov L; Piketty C;
    Lancet; 2024 Aug; 404(10451):445-460. PubMed ID: 39067461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
    Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
    Simpson EL; de Bruin-Weller M; Hong HC; Staumont-Sallé D; Blauvelt A; Eyerich K; Gooderham M; Shahriari M; Mallbris L; Atwater AR; Rueda MJ; Ding Y; Liu Z; Agell H; Silverberg JI
    Dermatol Ther (Heidelb); 2024 May; 14(5):1145-1160. PubMed ID: 38700646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis.
    Silverberg JI; Hong HC; Calimlim BM; Lee WJ; Teixeira HD; Collins EB; Crowell MM; Johnson SJ; Armstrong AW
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2247-2264. PubMed ID: 37658223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
    Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
    Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.